Pharmaceutical & BioTech

Preparing Pricing & Reimbursement (P&R) dossiers is an intricate blend of diverse expertise: a submission team encompasses medical writers, health economists, data analysts, and market access experts. Close interaction between writing and modeling teams optimizes the submission’s outcome.

RPN offers such comprehensive support.

A compelling submission dossier weaves a seamless narrative that advocates for a new treatment’s value proposition. Submission requirements differ between countries, but all require clear communication of the new product’s value.

The narrative flows from illustrating the disease’s impact and the unmet medical need to highlighting the treatment’s patient benefits, innovative qualities (if applicable), and its alignment with efficient healthcare resource utilization.

Defining the target population for funded adoption of the new technology and estimating population size are paramount. This hinges on outlining the current treatment pathway following national clinical guidelines, indicating where the technology fits, and the existing treatments it could potentially replace. These treatments, termed comparators, differ from clinical trials where a single comparator is common. In HTA, new technologies are evaluated against all existing treatments.

The clinical section of the dossier should notably present the pivotal clinical trial, providing a clear view of the trial methodology and the population involved.

The combination with a gap analysis, addressing evidence gaps, such as missing head-to-head data or health-related quality of life information, is equally crucial, with explanations on how these gaps will be tackled in the submission.

Striving to facilitate swift patient access to novel medicines, HTA (Health Technology Assessment) dossiers are frequently developed even before regulatory approval is secured. Moreover, in certain instances a definitive value narrative might still be absent. Ensuring clarity on these aspects within the submission team is crucial, as it lays the foundation for a coherent argument. While the clinical segment of the submission should present an unbiased view of the health condition, it should notably emphasize the requirements addressed by the new product, encompassing perspectives from both patients and the healthcare system.

Clear communication of clinical evidence and economic models is imperative, all while overseeing the comprehensive dossier.